In this exploratory, single-arm, nonrandomized trial, the impact of the preoperative utilization of the glucagon-like peptide-1 (GLP-1) receptor agonist (RA) semaglutide prior to radical prostatectomy in participants with intermediate risk prostate cancer will be investigated. Semaglutide will be administered according to the FDA-approved label for chronic weight management and participants will be dosed with a weekly subcutaneous injection. The primary aim of this trial is to explore the tumor biological activity of semaglutide in these participants. The trial will also evaluate the safety and tolerability of this preoperative treatment, along with the impact on physiologic/metabolic parameters.
Inclusion Criteria:
Exclusion Criteria:
nibu.mathew@bannerhealth.com480-256-3425
Participants enrolled in this single-arm study will receive weekly subcutaneous semaglutide for 3 to 6 months prior to planned radical prostatectomy. Semaglutide will be administered according to the FDA-approved dosing regimen, with dose titration as tolerated. Treatment will be discontinued one week prior to surgery, after which participants will proceed with standard-of-care radical prostatectomy and postoperative follow-up.
Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
Exisulind Prior to Radical Prostatectomy
Degarelix Before Radical Prostatectomy
Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy